REGN9933
REGN9933Regeneron entering Phase 3 anticoagulation with two large 2026 trials: AF (n=2,628) and PAD (n=7,050). Largest combined enrollment in the FXIa class.
Target: F11 monoclonal antibody (anti-FXI) Regeneron Pharmaceuticals Cardiometabolic
When will we know if it works?
Fresh est.A positive readout makes F11 a validated target for the first time. Hover the badge above for what the confidence level means.
2
Phase 3 trials
2 active · 0 completed
7
Total trials
P2: 3 · P1: 2
7,050
Max trial size
across 4 indications
1
Sponsors at target
incl. 3 other assets
What does it do?
F11 — Coagulation Factor XI / FXIa
Modality: monoclonal antibody (anti-FXI)
The 2 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT07430956 | Atrial Fibrillation (AF) | 2,628 | NOT_YET_RECRUITING | 2026-03-18 | 2029-03-28 | Fresh est. |
| NCT07318610 | Peripheral Artery Disease (PAD) | 7,050 | NOT_YET_RECRUITING | 2026-03-31 | 2029-05-05 | Fresh est. |
What's the case for and against?
✓ What's working in its favor
- Phase 2 VTE prevention positive readout 2024
Who else is racing? — 3 other assets at F11
| Asset | Sponsor | Status |
|---|---|---|
| Abelacimab | Anthos | AZALEA-TIMI-71 positive in AF |
| Asundexian | Bayer | P3 halted 2023 |
| Milvexian | BMS/Janssen | P3 LIBREXIA in stroke |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.